Skin Cancer

Mohs micrographic presents challenges in kids
November 25, 2020

While Mohs micrographic surgery is well established as a safe and effective therapeutic modality in adult patients, it is not as commonly used in pediatric populations. There are unique challenges to performing Mohs surgery on pediatric patients, especially with patient cooperation. Multidisciplinary planning may be needed.

The Cutaneous Connection- Episode 11: Racial Disparities in Melanoma Awareness
November 19, 2020

Neelam Vashi, M.D., FAAD, discusses the publication of her cross-sectional survey in the Journal of the American Academy of Dermatology regarding how different racial and ethnic groups possess various levels of melanoma awareness.

Future of immunotherapy in melanoma to focus on overcoming resistance, personalizing regimens
November 19, 2020

With an estimated 5-year survival rate of 50% and an ongoing issue of resistance, next steps with immunotherapy in melanoma will focus on stratifying patients, personalizing therapy, and refining localized regimens.

Smartphone apps not effective in skin cancer risk
November 17, 2020

Researchers conducted a critical appraisal of a systematic review of six different smartphone apps and found little evidence that they are effective in self-monitoring or skin cancer detection, according to a recent study.

Women surgeons and Mohs micrographic surgery in the U.S.
October 21, 2020

Michelle Nguyen, M.D., MPH, sits down with Dermatology Times to discuss her recent presentation at the 2020 American Society for Dermatologic Surgery (ASDS) virtual meeting regarding the representation of women dermatologic surgeons in the U.S.

Melanoma in situ: Imaging technique improves margin mapping
October 10, 2020

Performing reflectance confocal microscopy (RCM) with a mosaic technique before surgery can improve margin mapping in melanoma in situ (MIS), according to a recent study presented at 2020 ASDS Virtual Annual Meeting.

Racial disparities persist, worsen in melanoma survival
October 02, 2020

Today's universal improvement in melanoma survival is encouraging. But the reality is racial disparities aren’t going away and in some cases are getting worse.

New descriptor better distinguishes melanoma from benign lesions
October 01, 2020

A new descriptor may help providers to differentiate melanoma from benign lesions, says authors of a recent study.

Are your patients sunscreen savvy?
September 18, 2020

A recent survey shows that many consumers are confused about sunscreen labeling claims regarding sun protection factor (SPF), allergenicity and other features.

Spartalizumab phase 3 combination study fails to meet primary endpoint
September 14, 2020

Novartis announces their phase 3 study investigating spartalizumab (PDR001) in combination with dabrafenib (Tafinlar) and trametinib (Mekinist) failed to meet its primary endpoint.